Cargando…
Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
Autores principales: | Clemens, Paula R., Hoffman, Eric P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657699/ https://www.ncbi.nlm.nih.gov/pubmed/37955094 http://dx.doi.org/10.3233/JND-239005 |
Ejemplares similares
-
Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2023) -
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Clemens, Paula R., et al.
Publicado: (2022) -
Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience
por: Roshmi, Rohini Roy, et al.
Publicado: (2021) -
Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study
por: Clemens, Paula R., et al.
Publicado: (2023) -
Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study
por: Komaki, Hirofumi, et al.
Publicado: (2020)